| # | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ALA1040691 | F | NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | organism-based format | Novartis Malaria Screening | ||
| 2. | ALA1040692 | F | NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay | Plasmodium falciparum | 5,614 | organism-based format | Novartis Malaria Screening | ||
| 3. | ALA1040693 | T | NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7) | Homo sapiens | 5,614 | cell-based format | Novartis Malaria Screening | ||
| 4. | ALA1040694 | F | NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested. | 5,614 | assay format | Novartis Malaria Screening | |||
| 5. | ALA1789905 | F | NOVARTIS: Antimalarial liver stage activity measured as a greater than 50% reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells at 10uM compound concentration, determined by immuno-fluorescence. | Plasmodium yoelii | 4,416 | organism-based format | Novartis Malaria Screening | ||
| 6. | ALA1789906 | F | NOVARTIS: Antimalarial liver stage activity measured as reduction in Plasmodium yoelii schizont area in HepG2-A16-CD81 cells by immuno-fluorescence, and median schizont size at 10uM compound concentration | Plasmodium yoelii | 338 | organism-based format | Novartis Malaria Screening | ||
| 7. | ALA1794584 | F | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | 63,980 | assay format | PubChem BioAssays | |||
| 8. | ALA1963863 | F | PubChem BioAssay. qHTS for Inhibitors of Vif-A3G Interactions: qHTS. (Class of assay: confirmatory) | 8,558 | assay format | PubChem BioAssays | |||
| 9. | ALA2114716 | F | PubChem BioAssay. A Quantitative High throughput Screen to Identify Chemical Modulators of PINK1 Expression. (Class of assay: confirmatory) | Homo sapiens | 10,287 | assay format | PubChem BioAssays | ||
| 10. | ALA2114738 | F | PubChem BioAssay. qHTS for Inhibitors of Glutaminase (GLS). (Class of assay: confirmatory) | Homo sapiens | 15,494 | assay format | PubChem BioAssays | ||
| 11. | ALA2114784 | F | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | Homo sapiens | 53,810 | assay format | PubChem BioAssays | ||
| 12. | ALA2114836 | F | PubChem BioAssay. qHTS Assay for Inhibitors of the HIV-1 protein Vpr. (Class of assay: confirmatory) | Human immunodeficiency virus 1 | 14,580 | assay format | PubChem BioAssays | ||
| 13. | ALA2354211 | F | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-IDH1KD cell line. (Class of assay: confirmatory) | 35,070 | cell-based format | PubChem BioAssays | |||
| 14. | ALA2354221 | F | PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT. (Class of assay: confirmatory) | 172,532 | assay format | PubChem BioAssays | |||
| 15. | ALA2354254 | F | PubChem BioAssay. qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT. (Class of assay: confirmatory) | 153,867 | assay format | PubChem BioAssays | |||
| 16. | ALA2354311 | F | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | 31,581 | cell-based format | PubChem BioAssays | |||
| 17. | ALA3215270 | F | PubChem BioAssay. qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS. (Class of assay: confirmatory) | 22,758 | assay format | PubChem BioAssays | |||
| 18. | ALA3215278 | F | PubChem BioAssay. qHTS for Inhibitors of PLK1-PDB (polo-like kinase 1 - polo-box domain): Primary Screen. (Class of assay: confirmatory) | 23,091 | assay format | PubChem BioAssays | |||
| 19. | ALA3214801 | F | PubChem BioAssay. High Content Cell-Based Imaging Primary HTS to Identify autofluorescent compounds using cells not inducing Measured in Cell-Based System Using Imaging - 7015-02_Activator_Dose_CherryPick_Activity. (absACnn = the concentration at which the curve crosses threshold nn uM) (Class of assay: confirmatory) | 130 | cell-based format | PubChem BioAssays | |||
| 20. | ALA3562077 | F | PubChem BioAssay. High Throughput Screening for Foot and Mouth Disease Virus Antivirals. (Class of assay: confirmatory) | 69,295 | assay format | PubChem BioAssays |
The page will load shortly, Thanks for your patience!